{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:30Z","timestamp":1790239410674,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3462-5","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T08:39:43Z","timestamp":1542011983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-4289","authenticated-orcid":false,"given":"Andrea","family":"Giacomelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Stefania","family":"Falvella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Oreni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Renisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Di Cristo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lisa","family":"Ridolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"3462_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1586\/14787210.2.3.367","volume":"2","author":"A Milinkovic","year":"2004","unstructured":"Milinkovic A, Mart\u00ednez E. Nevirapine in the treatment of HIV. Expert Rev Anti-Infect Ther. 2004;2:367\u201373.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"37","key":"3462_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004890","volume":"95","author":"P De Boissieu","year":"2016","unstructured":"De Boissieu P, Dram\u00e9 M, Raffi F, et al. Dat\u2019AIDS study group. Long-term efficacy and toxicity of abacavir\/lamivudine\/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide cohort study. Medicine (Baltimore). 2016;95(37):e4890.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"3462_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1310\/hct1102-110","volume":"11","author":"V Reliquet","year":"2010","unstructured":"Reliquet V, Allavena C, Morineau-Le Houssine P, Mounoury O, Raffi F. Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients. HIV Clin Trials. 2010;11(2):110\u20137.","journal-title":"HIV Clin Trials"},{"issue":"6","key":"3462_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128131","volume":"10","author":"JM Llibre","year":"2015","unstructured":"Llibre JM, Bravo I, Ornelas A, et al. Effectiveness of a treatment switch to Nevirapine plus Tenofovir and Emtricitabine (or lamivudine) in adults with HIV-1 suppressed viremia. PLoS One. 2015;10(6):e0128131.","journal-title":"PLoS One"},{"issue":"2","key":"3462_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/00126334-200402010-00003","volume":"35","author":"SM Patel","year":"2004","unstructured":"Patel SM, Johnson S, Belknap SM, et al. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):120\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl. 1","key":"3462_CR6","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00126334-200309011-00005","volume":"34","author":"JO Stern","year":"2003","unstructured":"Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34(Suppl. 1):S21\u201333.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl. 2","key":"3462_CR7","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1086\/381450","volume":"38","author":"DT Dieterich","year":"2004","unstructured":"Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38(Suppl. 2):S80\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3462_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171596","volume":"12","author":"PY Wu","year":"2017","unstructured":"Wu PY, Cheng CY, Liu CE, et al. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-na\u00efve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. PLoS One. 2017 Feb 21;12(2):e0171596.","journal-title":"PLoS One"},{"key":"3462_CR9","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/QAD.0b013e32832d3b54","volume":"23","author":"AM Kesselring","year":"2009","unstructured":"Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS. 2009;23:1689\u201399.","journal-title":"AIDS"},{"issue":"3","key":"3462_CR10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/135965350701200305","volume":"12","author":"A Mocroft","year":"2007","unstructured":"Mocroft A, Staszewski S, Weber R, et al. EuroSIDA study group. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-na\u00efve and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther. 2007;12(3):325\u201333.","journal-title":"Antivir Ther"},{"issue":"7","key":"3462_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1468-1293.2012.00995.x","volume":"13","author":"B Van Welzen","year":"2012","unstructured":"Van Welzen B, Mudrikova T, Arends J, Hoepelman A. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients. HIV Med. 2012;13(7):448\u201352.","journal-title":"HIV Med."},{"issue":"6","key":"3462_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/428093","volume":"191","author":"I Sanne","year":"2005","unstructured":"Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825\u20139.","journal-title":"J Infect Dis"},{"key":"3462_CR13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","volume":"27","author":"P Riska","year":"1999","unstructured":"Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999;27:895\u2013901.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"3462_CR14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/FPC.0b013e32835a5af2","volume":"22","author":"J Bertrand","year":"2012","unstructured":"Bertrand J, Chou M, Richardson DM, et al. ANRS 12154 study group. Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet Genomics. 2012;22(12):868\u201376.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"3462_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1468-1293.2007.00432.x","volume":"8","author":"SR Penzak","year":"2007","unstructured":"Penzak SR, Kabuye G, Mugyenyi P, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 2007;8(2):86\u201391.","journal-title":"HIV Med"},{"key":"3462_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/jac\/dkn029","volume":"61","author":"C Wyen","year":"2008","unstructured":"Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;61:914\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"3462_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","volume":"15","author":"M Rotger","year":"2005","unstructured":"Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1\u20135.","journal-title":"Pharmacogenet Genomics"},{"key":"3462_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1742-7843.2011.00780.x","volume":"109","author":"C Gozalo","year":"2011","unstructured":"Gozalo C, Grard L, Loiseau P, et al. For the ANRS 081 study group pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with Nevirapine-containing regimen in anti-retroviral-nave HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic & Clinical Pharmacology & Toxicology. 2011;109:513\u201320.","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"3462_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1086\/507097","volume":"43","author":"DW Haas","year":"2006","unstructured":"Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43:783\u20136.","journal-title":"Clin Infect Dis"},{"key":"3462_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2217\/pgs.09.142","volume":"11","author":"C Ciccacci","year":"2010","unstructured":"Ciccacci C, Borgiani P, Ceffa S, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics. 2010;11:23\u201331.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"3462_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","volume":"17","author":"G Danan","year":"2016","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14.","journal-title":"Int J Mol Sci"},{"key":"3462_CR22","first-page":"343","volume":"13","author":"S Br\u00fcck","year":"2008","unstructured":"Br\u00fcck S, Witte S, Brust J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res. 2008;13:343\u20138.","journal-title":"Eur J Med Res"},{"key":"3462_CR23","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/932542","volume":"2012","author":"Z Bekker","year":"2012","unstructured":"Bekker Z, Walubo A, du Plessis JB. The role of the immune system in Nevirapine-induced subclinical liver injury of a rat model. ISRN Pharmaceutics. 2012;2012:932542.","journal-title":"ISRN Pharmaceutics"},{"issue":"1 Suppl","key":"3462_CR24","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","volume":"44","author":"M N\u00fa\u00f1ez","year":"2006","unstructured":"N\u00fa\u00f1ez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44(1 Suppl):S132\u20139 Epub 2005 Nov 28.","journal-title":"J Hepatol"},{"key":"3462_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.283.1.74","volume":"283","author":"MS Sulkowski","year":"2000","unstructured":"Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74\u201380.","journal-title":"JAMA"},{"issue":"5","key":"3462_CR26","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/jac\/dkp044","volume":"63","author":"M Vogel","year":"2009","unstructured":"Vogel M, Bertram N, Wasmuth JC, Wyen C, Voigt E, Schwarze-Zander C, Sudhop T, F\u00e4tkenheuer G, Rockstroh JK, Reichel C. Nevirapine pharmacokinetics in HIV-infected and HIV\/HCV-coinfected individuals. J Antimicrob Chemother. 2009 May;63(5):988\u201391.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"3462_CR27","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1124\/dmd.108.024851","volume":"37","author":"B Wen","year":"2009","unstructured":"Wen B, Chen Y, Fitch WL. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos. 2009 Jul;37(7):1557\u201362.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"3462_CR28","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1093\/jac\/dkr087","volume":"66","author":"A Schipani","year":"2011","unstructured":"Schipani A, Wyen C, Mahungu T, et al. German competence network for HIV\/AIDS. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother. 2011;66(6):1332\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3462_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1468-1293.2008.00689.x","volume":"10","author":"T Mahungu","year":"2009","unstructured":"Mahungu T, Smith C, Turner F, et al. Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 2009 May;10(5):310\u20137.","journal-title":"HIV Med."},{"key":"3462_CR30","doi-asserted-by":"publisher","first-page":"205031211878086","DOI":"10.1177\/2050312118780861","volume":"6","author":"A Giacomelli","year":"2018","unstructured":"Giacomelli A, Rusconi S, Falvella FS, et al. Clinical and genetic determinants of nevirapine plasma trough concentration. SAGE Open Med. 2018;6:2050312118780861.","journal-title":"SAGE Open Med"},{"issue":"10","key":"3462_CR31","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","volume":"25","author":"J Yuan","year":"2011","unstructured":"Yuan J, Guo S, Hall D, et al. Nevirapine Toxicogenomics study team. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS. 2011;25(10):1271\u201380.","journal-title":"AIDS"},{"key":"3462_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/01.fpc.0000236338.41799.57","volume":"16","author":"A Owen","year":"2006","unstructured":"Owen A, Pirmohamed M, Khoo HS, Back DJ. Pharmacogenetics of HIV therapy. Pharmacogenet Genomics. 2006;16:693\u2013703.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"3462_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013 Apr;138(1):103\u201341.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3462_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1515\/dmdi-2012-0031","volume":"28","author":"JP Kitzmiller","year":"2013","unstructured":"Kitzmiller JP, Sullivan DM, Phelps MA, Wang D, Sadee W. CYP3A4\/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug Metabol Drug Interact. 2013;28(1):59\u201363.","journal-title":"Drug Metabol Drug Interact"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3462-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3462-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3462-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:21:28Z","timestamp":1775265688000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3462-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3462"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3462-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"13 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by our ethics committee (Comitato Etico Interaziendale, Milano area 1); all subjects signed a dedicated informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.R. has received consultancy payments and speaking fee from Bristol-Myers Squibb, Gilead, ViiV Healthcare, Merck Sharp Dohme, ABBvie and Janssen. M.G. has received consultancy payments and speaking fee from Bristol-Myers Squibb, Gilead, ViiV Healthcare, Merck Sharp Dohme, ABBvie, Janssen and Roche.Preliminary data of this study were presented as poster presentation (PE10\/15) at the 16th European AIDS conference, October 25\u201327, 2017 Milan, Italy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"556"}}